Search Results - on behalf of the K-877 Study Group

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

    Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized... by Arai, Hidenori, Yamashita, Shizuya, Yokote, Koutaro, Araki, Eiichi, Suganami, Hideki, Ishibashi, Shun, on behalf of the K-877 Study Group

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels : A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

    Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels : A Multicenter, Placebo-Controlled, Double-Blind, Randomize... by Hidenori Arai, Shizuya Yamashita, Koutaro Yokote, Eiichi Araki, Hideki Suganami, Shun Ishibashi, on behalf of the K- Study Group

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

    Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment by Yokote, Koutaro, Yamashita, Shizuya, Arai, Hidenori, Araki, Eiichi, Suganami, Hideki, Ishibashi, Shun, Of The K-Study Group, On Behalf

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia

    Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind... by Arai, Hidenori, Yamashita, Shizuya, Yokote, Koutaro, Araki, Eiichi, Suganami, Hideki, Ishibashi, Shun

    Published in Atherosclerosis
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: